World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 31 October 2022
Main ID:  NCT03241121
Date of registration: 02/04/2017
Prospective Registration: Yes
Primary sponsor: University of Lausanne Hospitals
Public title: Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
Scientific title: Study of Eating Patterns With a Smartphone App and the Metabolic Effects of Time Restricted Feeding (TRF) in the Metabolic Syndrome - An Open-label Randomized Controlled Trial of TRF vs Regular Dietary Advices
Date of first enrolment: September 29, 2017
Target sample size: 235
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT03241121
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  N/A
Countries of recruitment
Switzerland
Contacts
Name:     Tinh-Hai Collet, MD
Address: 
Telephone:
Email:
Affiliation:  University of Lausanne Hospitals
Key inclusion & exclusion criteria

Key inclusion criteria for both observation and intervention phases (Part 1+2):

- Age = 12 years

- Body mass index = 20 kg/m2 and stable weight (previous 3 months) in adults; BMI = 25th
percentile in teenagers

- Smartphone compatible with the app (iOS or Android systems)

Additional inclusion criteria for the intervention phase (Part 2):

- Any component of the metabolic syndrome following the International Diabetes
Federation consensus definition

- Eating duration >14h during the observation phase

Additional inclusion criteria for the mechanistic study (Part 3):

- Age 18-40 years, men and pre-menopausal women

- BMI 30-40 kg/m2

- In the fasting state (at least 8 hours)

Key exclusion criteria for both observation and intervention phases (Part 1+2):

- Pregnant and breastfeeding women, plans for maternity during the study

- Major illness/fever over the previous month, active cancer

- Eating disorder, on a diet / weight management, prior bariatric surgery

- Major mental illness, unable to give informed consent

- Current shift work or travel abroad planned in the next month

Additional exclusion criteria for the intervention phase (Part 2):

- Prior cardiovascular event

- Major liver, gastrointestinal, renal or endocrine disorder, diabetes mellitus with
hypoglycemic drug(s)

- Major sleep disorder, centrally acting medication

- Lipid lowering drug, hypoglycemic drug, medication affecting the gut

Additional exclusion criteria for the mechanistic study (Part 3):

- Impaired glucose tolerance (pre-diabetes) or diabetes mellitus

- Positive pregnancy test



Age minimum: 12 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Steatosis of Liver
Eating Behavior
Obesity
Dyslipidemias
Glucose Intolerance
Metabolic Syndrome
Intervention(s)
Device: Eating patterns
Behavioral: Time restricted feeding
Behavioral: Regular dietary advices
Primary Outcome(s)
Change of metabolic syndrome components [Time Frame: From baseline visit to close-out visit (Part 1: 4 weeks for adults, 2 weeks for teenagers; followed by Part 2: 6 months for adults, 6 weeks for teenagers)]
Eating duration [Time Frame: From baseline visit to end of observation phase (Part 1: 4 weeks for adults, 2 weeks for teenagers)]
Secondary Outcome(s)
Change in meal intervals [Time Frame: From baseline visit to close-out visit (Part 1: 4 weeks for adults, 2 weeks for teenagers; followed by Part 2: 6 months for adults, 6 weeks for teenagers)]
Change in eating pattern difference between weekdays and weekends [Time Frame: From baseline visit to close-out visit (Part 1: 4 weeks for adults, 2 weeks for teenagers; followed by Part 2: 6 months for adults, 6 weeks for teenagers)]
Change in lipid profile [Time Frame: From baseline visit to close-out visit (Part 1: 4 weeks for adults, 2 weeks for teenagers; followed by Part 2: 6 months for adults, 6 weeks for teenagers)]
Change in number of meals per day [Time Frame: From baseline visit to close-out visit (Part 1: 4 weeks for adults, 2 weeks for teenagers; followed by Part 2: 6 months for adults, 6 weeks for teenagers)]
Change in fraction of calories consumed after 6pm [Time Frame: From baseline visit to close-out visit (Part 1: 4 weeks for adults, 2 weeks for teenagers; followed by Part 2: 6 months for adults, 6 weeks for teenagers)]
Change in fraction of calories consumed after noon [Time Frame: From baseline visit to close-out visit (Part 1: 4 weeks for adults, 2 weeks for teenagers; followed by Part 2: 6 months for adults, 6 weeks for teenagers)]
Change in blood pressure [Time Frame: From baseline visit to close-out visit (Part 1: 4 weeks for adults, 2 weeks for teenagers; followed by Part 2: 6 months for adults, 6 weeks for teenagers)]
Change in hepatic steatosis / fibrosis score [Time Frame: From randomization visit to close-out visit (Part 2: 6 months for adults, 6 weeks for teenagers)]
Change in glucose metabolism [Time Frame: From baseline visit to close-out visit (Part 1: 4 weeks for adults, 2 weeks for teenagers; followed by Part 2: 6 months for adults, 6 weeks for teenagers)]
Adherence to TRF intervention [Time Frame: From randomization visit to close-out visit (Part 2: 6 months for adults, 6 weeks for teenagers)]
Weight change [Time Frame: From baseline visit to close-out visit (Part 1: 4 weeks for adults, 2 weeks for teenagers; followed by Part 2: 6 months for adults, 6 weeks for teenagers)]
Secondary ID(s)
PZ00P3-167826
2017-00487
SSED-YI 2017
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Salk Institute for Biological Studies
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history